| 產品描述： | GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16. |
| 靶點： |
Stearoyl-CoA Desaturase (SCD);Dehydrogenase;?Stearoyl-CoADesaturase(SCD) |
| 體外研究： |
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD), which can be used to treat and/or preventing various diseases, including those mediated by SCD enzyme, such as diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, skin disorders such as acne, diseases or conditions related to cancer and the treatment of symptoms linked to the production of the amyloid plaque-forming Aβ42 peptide such as Alzheimer's disease |
| 參考文獻： |
1. Anne Marie Jeanne Bouillot, et al. 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors . PCT Int. Appl. (2009), WO 2009060053 A1 20090514. |
| 溶解性： |
soluble in DMSO |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.556 ml |
12.78 ml |
25.559 ml |
| 5 mM |
0.511 ml |
2.556 ml |
5.112 ml |
| 10 mM |
0.256 ml |
1.278 ml |
2.556 ml |
| 50 mM |
0.051 ml |
0.256 ml |
0.511 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京